Nipro Corporation to Acquire Infraredx
Nipro Corporation (Osaka, Japan) has signed a definitive agreement to acquire Infraredx, Inc. (Burlington, Massachusetts).
Nipro Corporation (Osaka, Japan) has signed a definitive agreement to acquire Infraredx, Inc. (Burlington, Massachusetts). Nipro Corporation has broad holdings in pharmaceuticals and medical devices. Infraredx is an intravascular imaging company working to advance the diagnosis and management of coronary artery disease globally.
The agreement combines Nipro’s global cardiovascular portfolio with Infraredx’s industry expertise in near infrared spectroscopy and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States, and continue Infraredx’s mission to provide cardiologists with advanced imaging tools designed to predict heart attacks and prevent them.
“We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease,” Jason Bottiglieri, president and CEO of Infraredx, said in a statement.
The acquisition, which is subject to certain conditions, is expected to close in October 2015.
Newsletter
Get essential updates on the latest spectroscopy technologies, regulatory standards, and best practices—subscribe today to Spectroscopy.
AI-Powered Raman with CARS Offers Laser Imaging for Rapid Cervical Cancer Diagnosis
July 15th 2025Chinese researchers have developed a cutting-edge cervical cancer diagnostic model that combines spontaneous Raman spectroscopy, CARS imaging, and artificial intelligence to achieve 100% accuracy in distinguishing healthy and cancerous tissue.
How Analytical Chemists Are Navigating DOGE-Driven Funding Cuts
July 14th 2025DOGE-related federal funding cuts have sharply reduced salaries, lab budgets, and graduate support in academia. Researchers view the politically driven shifts in priorities as part of recurring systemic issues in U.S. science funding during administrative transitions. The impact on Federal laboratories has varied, with some seeing immediate effects and others experiencing more gradual effects. In general, there is rising uncertainty over future appropriations. Sustainable recovery may require structural reforms, leaner administration, and stronger industry-academia collaboration. New commentary underscores similar challenges, noting scaled-back graduate admissions, spending freezes, and a pervasive sense of overwhelming stress among faculty, students, and staff. This article addresses these issues for the analytical chemistry community.
